PRAME (PReferentially expressed Antigen in Melanoma) immunohistochemistry (IHC) has proven its diagnostic utility in differentiating between benign melanocytic tumors and malignant melanocytic tumors [1]. This evidence concerns the gene PRAME and melanoma.